Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05717140CT.gov Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | — | Withdrawn | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT02339571CT.gov A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | — | Active Not Recruiting | — | — | — |
NCT01134614CT.gov Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT00436930CT.gov Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma | — | Completed | — | — | — |
NCT00568763CT.gov Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | — | Completed | — | — | — |
NCT00278122CT.gov Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | — | Suspended | — | — | — |
NCT00071981CT.gov Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00118313CT.gov Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | — | Completed | — | — | — |
NCT00085579CT.gov Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | — | Withdrawn | — | — | — |
Show 19 more trialsShow fewer
NCT00085423CT.gov Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00089193CT.gov Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | — | Completed | — | — | — |
NCT00089206CT.gov Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00017121CT.gov Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung | — | Completed | — | — | — |
NCT00031733CT.gov Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma | — | Completed | — | — | — |
NCT00037037CT.gov Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma | — | Unknown | — | — | — |
NCT00005610CT.gov Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung | — | Completed | — | — | — |
NCT00006385CT.gov Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT01989572CT.gov Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery | — | Completed | — | — | — |
NCT00014092CT.gov Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery | — | Completed | — | — | — |
NCT00006113CT.gov Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | — | Terminated | — | — | — |
NCT00003897CT.gov Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma | — | Completed | — | — | — |
NCT00004184CT.gov Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | — | Completed | — | — | — |
NCT00003362CT.gov Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma | — | Completed | — | — | — |
NCT00003222CT.gov Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | — | Completed | — | — | — |
NCT00003274CT.gov Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery | — | Completed | — | — | — |
NCT00019383CT.gov Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma | — | Completed | — | — | — |
NCT00019331CT.gov Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00002817CT.gov Vaccine Therapy in Treating Patients With Metastatic Melanoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sargramostim (this asset) | Mayo Clinic | P3 | BB · 68 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Cediranib | Jonsson Comprehensive Cancer Center | P3 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Sargramostim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Chronic Myeloid Leukemia | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sargramostim in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sargramostim-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →